CSC
CRSP icon

Caldwell Sutter Capital’s CRISPR Therapeutics CRSP Stock Holding History

Caldwell Sutter Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15
Closed -$939 – 931
2023
Q4 		$939 Buy
+15
New +$829 ﹤0.01% 837

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caldwell Sutter Capital's CRSP Position: Q1 2024 in Review

Caldwell Sutter Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 15 shares — an estimated $939 sold.

Caldwell Sutter Capital first reported a position in CRSP in Q4 2023 and held it in 1 quarter. The position peaked at $939 in Q4 2023. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Caldwell Sutter Capital reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Caldwell Sutter Capital sold 15 CRISPR Therapeutics shares in Q1 2024, an estimated $939.
  • Caldwell Sutter Capital first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 1 quarter.
  • Caldwell Sutter Capital's CRISPR Therapeutics position peaked at $939 in Q4 2023.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Caldwell Sutter Capital's 13F filing for Q1 2024, filed 19 Apr 2024.